ライフサイエンスコーパス: ursodiol

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 s despite treatment with corticosteroids and ursodiol.

2 ted serum bile acids responded positively to ursodiol.

3 e alone or in combination with colchicine or ursodiol.

4 n a randomized, double-blind study comparing ursodiol (13 to 15 mg per kilogram of body weight per da

5 , patients were randomly assigned to receive ursodiol, 300 mg twice daily (or 300 mg in the morning a

6 ed in combination with ursodeoxycholic acid (ursodiol), a naturally occurring 7-B-epimer of the bile

7 Treatment with ursodiol, a more hydrophilic bile acid, improved pruritu

8 re likely to progress despite treatment with ursodiol and understand the putative new bile acid and i

9 linical trials demonstrating the efficacy of ursodiol as a treatment for PBC were published, although

10 of obeticholic acid or placebo, 93% received ursodiol as background therapy.

11 Ursodiol, but not placebo, was associated with improveme

12 Unconjugated ursodiol bypassed the hepatic uptake block to enlarge th

13 In contrast, unconjugated ursodiol entered the liver and was conjugated and secret

14 as not statistically significant (13% in the ursodiol group and 20% in the placebo group; P > 0.2).

15 e (relative risk of treatment failure in the ursodiol group, 1.01; 95 percent confidence interval, 0.

16 acebo group and 16 of 31 (52 percent) in the ursodiol group.

17 Ursodiol has been shown to protect against development o

18 Ursodiol improves serum aminotransferase levels in chron

19 investigating the chemoprotective effect of ursodiol in patients with ulcerative colitis may be warr

20 er liver transplantation, and the success of ursodiol in treatment.

21 e published, although it has been clear that ursodiol is not a cure and only delays progression in so

22 Obeticholic acid administered with ursodiol or as monotherapy for 12 months in patients wit

23 Treatment of primary biliary cirrhosis with ursodiol or colchicine may stabilize the disease or slow

24 7 patients who had an inadequate response to ursodiol or who found the side effects of ursodiol unacc

25 Ursodiol prophylaxis seemed to decrease the incidence of

26 well-defined primary sclerosing cholangitis, ursodiol provided no clinical benefit.

27 ebo recipients and 15% (5 of 34 patients) in ursodiol recipients (P = 0.03).

28 On ursodiol therapy, hepatic bile acid synthesis was enhanc

29 can progress to cirrhosis and death despite ursodiol therapy.

30 to ursodiol or who found the side effects of ursodiol unacceptable to receive obeticholic acid at a d

31 Ursodiol (ursodeoxycholic acid) benefits patients with p

32 Ursodiol use appears to be associated with a lower frequ

33 The association between dysplasia and ursodiol use remained after adjustment for sex, age at o

34 Ursodiol use was strongly associated with decreased prev

35 Use of ursodiol was assessed in all patients.

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。